Manuel Afable

2.5k total citations
32 papers, 1.3k citations indexed

About

Manuel Afable is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Manuel Afable has authored 32 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 11 papers in Genetics and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Manuel Afable's work include Acute Myeloid Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Manuel Afable is often cited by papers focused on Acute Myeloid Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Manuel Afable collaborates with scholars based in United States, Japan and Germany. Manuel Afable's co-authors include Jaroslaw P. Maciejewski, Ramón V. Tiu, Mikkael A. Sekeres, Hideki Makishima, A. Jankowska, Christine L. O’Keefe, Andrés Jerez, Michael A. McDevitt, Bartlomiej Przychodzen and Hadrian Szpurka and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Manuel Afable

29 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manuel Afable United States	17	911	580	491	260	184	32	1.3k
Azim Mohamedali United Kingdom	18	1.1k 1.2×	499 0.9×	500 1.0×	215 0.8×	164 0.9×	37	1.4k
Andrés Jerez Spain	17	793 0.9×	639 1.1×	593 1.2×	527 2.0×	358 1.9×	60	1.6k
Hadrian Szpurka United States	17	1.4k 1.6×	939 1.6×	972 2.0×	178 0.7×	145 0.8×	35	2.0k
Andrew Duncombe United Kingdom	18	1.1k 1.2×	1.2k 2.1×	915 1.9×	174 0.7×	149 0.8×	35	2.0k
Anna Jankowska United States	15	494 0.5×	390 0.7×	324 0.7×	188 0.7×	100 0.5×	27	939
Ana Rasillo Spain	20	992 1.1×	560 1.0×	597 1.2×	259 1.0×	316 1.7×	22	1.5k
Nathalie Grardel France	15	848 0.9×	322 0.6×	591 1.2×	180 0.7×	237 1.3×	40	1.3k
Janice M. Hodnefield United States	18	1.3k 1.4×	727 1.3×	763 1.6×	150 0.6×	356 1.9×	28	1.7k
Anna Aventı́n Spain	20	495 0.5×	372 0.6×	317 0.6×	147 0.6×	232 1.3×	58	938
Barbara Crescenzi Italy	18	476 0.5×	344 0.6×	235 0.5×	144 0.6×	161 0.9×	55	1.0k

Countries citing papers authored by Manuel Afable

Since Specialization

Citations

This map shows the geographic impact of Manuel Afable's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Afable with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Afable more than expected).

Fields of papers citing papers by Manuel Afable

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Afable. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Afable. The network helps show where Manuel Afable may publish in the future.

Co-authorship network of co-authors of Manuel Afable

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Afable. A scholar is included among the top collaborators of Manuel Afable based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Afable. Manuel Afable is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kasi, Pashtoon Murtaza, et al.. (2023). Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer. The Oncologist. 28(12). 1034–1048. 20 indexed citations

Gathirua‐Mwangi, Wambui G., et al.. (2022). Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer. Future Oncology. 18(29). 3299–3310.

Tannir, Nizar M., Kyriakos P. Papadopoulos, Deborah J. Wong, et al.. (2021). Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. International Journal of Cancer. 149(2). 403–408. 29 indexed citations

Gathirua‐Mwangi, Wambui G., et al.. (2021). Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States. Journal of Medical Economics. 24(1). 1164–1172. 2 indexed citations

William, Basem M., Manuel Afable, Brenda Cooper, et al.. (2018). A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood. 132(Supplement 1). 1875–1875. 5 indexed citations

Clemente, Michael J., Manuel Afable, Andrés Jerez, et al.. (2017). Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leukemia & lymphoma. 59(2). 416–422. 68 indexed citations

Afable, Manuel, Paolo F. Caimi, Chitra Hosing, et al.. (2015). Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment. Biology of Blood and Marrow Transplantation. 21(8). 1529–1531. 5 indexed citations

Caimi, Paolo F., Brenda Cooper, Basem M. William, et al.. (2014). Phase I Trial of the Base – Excision Repair Blocker Methoxyamine (TRC-102) Combined with Fludarabine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies. Blood. 124(21). 4688–4688. 2 indexed citations

Skarbnik, Alan P, Craig A. Portell, Jaroslaw P. Maciejewski, et al.. (2013). Association Of Large Granular Lymphocytic Leukemia (LGL) With B-Cell Lymphoproliferative Disorders. Blood. 122(21). 1387–1387. 2 indexed citations

10.

Clemente, Michael J., Bartlomiej Przychodzen, Andrés Jerez, et al.. (2013). Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. Blood. 122(25). 4077–4085. 58 indexed citations

11.

Clemente, Michael J., Swapna Thota, Manuel Afable, et al.. (2013). Inhibition Of The JAK/STAT Signaling Pathway As a Novel Therapy In CD8+ T-Large Granular Lymphocyte Leukemia. Blood. 122(21). 3902–3902. 1 indexed citations

12.

Hasrouni, Edy, Heesun J. Rogers, Ali Tabarroki, et al.. (2013). A case of mistaken identity: When lupus masquerades as primary myelofibrosis. SHILAP Revista de lepidopterología. 1. 2050313X13498709–2050313X13498709. 3 indexed citations

13.

Sugimoto, Yuka, Mikkael A. Sekeres, Hideki Makishima, et al.. (2012). Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. Journal of Hematology & Oncology. 5(1). 4–4. 18 indexed citations

14.

Kar, Sarah Abu, Ania Jankowska, Hirokazu Makishima, et al.. (2012). Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica. 98(1). 107–113. 61 indexed citations

15.

Sekeres, Mikkael A., Ramón V. Tiu, Rami S. Komrokji, et al.. (2012). Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 120(25). 4945–4951. 98 indexed citations

16.

Afable, Manuel, Mohammed A. Shaik, Yuka Sugimoto, et al.. (2011). Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica. 96(9). 1269–1275. 75 indexed citations

17.

Sekeres, Mikkael A., Alan F. List, David Cuthbertson, et al.. (2010). Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology. 28(13). 2253–2258. 86 indexed citations

18.

Sekeres, Mikkael A., et al.. (2010). Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher‐risk myelodysplastic syndromes. American Journal of Hematology. 86(1). 102–103. 37 indexed citations

19.

Sekeres, Mikkael A., Jaroslaw P. Maciejewski, Harry P. Erba, et al.. (2010). A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer. 117(6). 1253–1261. 26 indexed citations

20.

Clemente, Michael J., Manuel Afable, Heather Cazzolli, et al.. (2009). Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica. 94(10). 1407–1414. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact